ARCA biopharma Revenue and Competitors
Estimated Revenue & Valuation
- ARCA biopharma's estimated annual revenue is currently $3.5M per year.
- ARCA biopharma's estimated revenue per employee is $140,000
- ARCA biopharma's total funding is $90.4M.
Employee Data
- ARCA biopharma has 25 Employees.
- ARCA biopharma grew their employee count by -7% last year.
ARCA biopharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.7M | 11 | 0% | N/A | N/A |
#2 | $2.8M | 18 | 13% | N/A | N/A |
#3 | $70.2M | 453 | -1% | N/A | N/A |
#4 | $1.6M | 10 | -66% | N/A | N/A |
#5 | $3.7M | 24 | -8% | N/A | N/A |
#6 | $2.9M | 37 | 28% | N/A | N/A |
#7 | $3.1M | 20 | 25% | N/A | N/A |
#8 | $2.5M | 16 | -20% | N/A | N/A |
#9 | $9.1M | 59 | 0% | N/A | N/A |
#10 | $4.2M | 27 | -7% | N/A | N/A |
What Is ARCA biopharma?
ARCA biopharma, Inc. is a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA biopharma began operations in 2005 and is headquartered in Broomfield, Colorado. The Company’s lead investigational product is Gencaro™ 1 (bucindolol hydrochloride), a genetically-targeted beta-blocker with unique pharmacology, in development for heart failure and other indications. ARCA’s New Drug Application for Gencaro for chronic heart failure, was accepted for filing by the U.S. Food and Drug Administration in September, 2008, and is currently under review by the FDA with a Prescription Drug User Fee Act (PDUFA) date of May 31, 2009.
keywords:N/A
$90.4M
Total Funding
25
Number of Employees
$3.5M
Revenue (est)
-7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ARCA biopharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO/President | Reveal Email/Phone |
2 | SVP/General Counsel | Reveal Email/Phone |
3 | Sr. Director, Quality | Reveal Email/Phone |
4 | Chief Operating Officer | Reveal Email/Phone |
5 | VP, Regulatory Affairs and Quality | Reveal Email/Phone |
ARCA biopharma News
ARCA biopharma, Inc, a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular...
ARCA biopharma is dedicated to developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine...
ARCA biopharma is dedicated to developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine...
Other Companies in Broomfield
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.2M | 25 | -4% | N/A |
#2 | N/A | 25 | -14% | N/A |
#3 | $5.1M | 27 | 8% | N/A |
#4 | $6.1M | 31 | -11% | N/A |
#5 | $5.2M | 32 | 0% | N/A |
ARCA biopharma Executives
| Name | Title |
|---|---|
| Michael Bristow | CEO/President |
| Thomas Keuer | Chief Operating Officer |
| Tom Keuer | Chief Operating Officer |
| Brian Selby | Vice President Finance & Chief Accounting Officer |
| Michael Bristow | CEO/President |
| Christopher Ozeroff | SVP/General Counsel |
| Monique Plamondon | VP Regulatory Affairs & Quality |
| Sharon Perry | Vice President, Regulatory Affairs and Quality |
| Brian Selby | Vice President Finance & Chief Accounting Officer |